Newsroom | 18461 results

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published in the peer-reviewed journal Human Gene Therapy. The publication highlights compelling preclinical evidence that Modalis’ proprietary CRISPR-GNDM® epigenome editing technology can safely and robustly activate the LAMA1 gene as a novel therapeutic s...

MILAN & HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals and Italfarmaco announced an exclusive licensing agreement for the development and commercialization of givinostat in Japan....

ROCHESTER, Minn.--(BUSINESS WIRE)--Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate....

DUBLIN--(BUSINESS WIRE)--The "Direct-to-Consumer Genetic Testing Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The direct-to-consumer genetic testing market is undergoing rapid transformation, driven by technological advancement, new regulatory dynamics, and changing consumer expectations. Senior leaders must navigate this evolving landscape by understanding underlying drivers influencing strategic positioning, operational resilience, and growth...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7 Interim Clinical Data – January 6, 2026 Type: Company KOL Webinar Date/Time: January 6, 2026, 11:30 a.m. EST J.P. Morgan 2026 Healthcare Conference – January 12-15, 2026 Type: Corporate Presentation Date/Time: January 12, 2026, 10:30 a.m. EST Presentation materials and webcast links, i...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units (“RSUs”) to a new employee under the Precision BioSciences, Inc. 2021 Employment In...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update. “We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Israel’s Ministry of Health Pharmaceutical Division has authorized the use of the candidate gene therapy GS010/LUMEVOQ®1 for the early access treatment of individual patients in the country. Early...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera websit...